Clinical Trial Conduct May Be Subject To DoJ Enforcement
Executive Summary
The Department of Justice is moving into the arena of FDA regulation - including a manufacturer's conduct of clinical trials - in its enforcement of fraud statutes
You may also be interested in...
Prosecutors Remain Aggressive In Investigating Off-Label Drug Promotion
The Philadelphia U.S. Attorney's investigations of off-label promotion include examination of drug information databases
Pfizer To Monitor Off-Label Drug Use Under Neurontin Settlement
Pfizer will provide periodic reports to the HHS Inspector General about off-label use trends for its products under the May 13 settlement of an investigation into the company's promotion of Neurontin
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011